Dermira (DERM) Reports Positive Topline Results from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis
Tweet Send to a Friend
Dermira, Inc. (NASDAQ: DERM) today announced positive results from a Phase 2b dose-ranging study of lebrikizumab, an investigational therapy, in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
